EuBiologics Co., Ltd.
KOE: 206650.KQ0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Yeong-Ok Baik
- Employees
- 323
- Headquarters
- Seoul, South Korea
- IPO year
- 2017
- Market cap
- ₩449.4B
- Website
- http://www.eubiologics.com
Loading 206650…
Loading profile data…Frequently asked questions about 206650
What does EuBiologics Co., Ltd. (206650.KQ) do?
EuBiologics Co., Ltd., a biopharmaceutical company, develops and supplies vaccines for epidemics and antibiotic resistance in South Korea. It offers Euvchol, an oral cholera prevention vaccine; and CRM197, a diphtheria toxin mutant vaccine. The company also provides customized services for mammalian cell and microbial cell derived biopharmaceuti...
Where does 206650.KQ trade?
EuBiologics Co., Ltd. (206650.KQ) trades on the KOSDAQ.
What sector is 206650.KQ in?
EuBiologics Co., Ltd. (206650.KQ) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of EuBiologics Co., Ltd.?
Yeong-Ok Baik is the chief executive officer of EuBiologics Co., Ltd. (206650.KQ).
Where is EuBiologics Co., Ltd. headquartered?
EuBiologics Co., Ltd. is headquartered in South Korea.
Does 206650.KQ pay a dividend?
EuBiologics Co., Ltd. (206650.KQ) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 206650.KQ go public?
EuBiologics Co., Ltd. (206650.KQ) completed its initial public offering in 2017.